AstraZeneca PLC Stock Performance
AstraZeneca PLC shares currently trade at $159.20, reflecting a modest decline of 0.28% over the past month and a more pronounced 6.06% pullback over three months, per SID market data. Despite near-term weakness, the stock has delivered a robust 85.4% gain over the trailing twelve months, significantly outperforming broader healthcare sector benchmarks. The stock is currently trading below both its 50-day moving average of $162.08 and its 200-day moving average of $168.91, indicating sustained downward pressure. The 14-day relative strength index stands at 31.4, approaching oversold territory and suggesting the selling momentum may be nearing exhaustion. AstraZeneca maintains a notably low beta of 0.168, according to Massive/Polygon data, underscoring its defensive characteristics relative to the broader market. Average daily volume stands at approximately 5.47 million shares, supporting adequate liquidity for institutional positioning.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC carries a market capitalization of approximately $279.9 billion, positioning it among the largest global pharmaceutical companies, per SID market data. The stock trades at a price-to-earnings ratio of 33.06, which commands a premium relative to the broader healthcare sector. The PEG ratio of 4.53, according to SEC filings and consensus growth estimates, suggests the current earnings multiple substantially exceeds the company's projected growth rate, indicating the stock may be richly valued on a growth-adjusted basis. AstraZeneca's price-to-book ratio stands at 6.24, reflecting significant intangible asset value associated with its pharmaceutical pipeline and intellectual property portfolio. The company offers a dividend yield of approximately 1.56%, providing modest income to shareholders. These valuation metrics collectively position AstraZeneca at a premium within its peer group, consistent with market expectations for continued pipeline-driven revenue expansion and oncology franchise growth.
Smart Money Activity for AZN
AstraZeneca PLC registers a smart money score of 59 with a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum conviction from large asset managers and reflecting strong positioning among hedge funds and mutual funds in recent 13F institutional filings. Insider activity scores 12.5 out of 25, with SEC Form 4 filings revealing three insider transactions over the past 90 days — all purchases and zero sales. This unanimous buying pattern among corporate insiders suggests internal confidence in the company's forward outlook, even as the stock experiences near-term price weakness. Dark pool activity registers a relatively low score of 9.2 out of 25, indicating limited off-exchange institutional block trading in recent periods. Congressional trading activity scores 12 out of 25, reflecting moderate engagement from elected officials. The divergence between robust institutional holdings and subdued dark pool activity warrants monitoring as technical conditions evolve.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC delivered a significant earnings surprise in its most recent reported quarter, posting actual earnings of $2.63 per share against an analyst consensus estimate of $1.52, representing a $1.11 positive surprise, according to company earnings reports. This 73% beat underscores strong operational execution across the company's oncology and biopharmaceuticals portfolio. Looking ahead, analyst estimates project earnings of $1.44 per share for the upcoming July 2026 quarter, followed by estimates of $1.35 for both the October and November 2026 reporting periods, per consensus analyst estimates. The sequential decline in estimates from $1.44 to $1.35 may reflect anticipated seasonality or pipeline investment timing. With three forward quarters carrying pending results, the trajectory of analyst revisions will be critical in determining whether the substantial beat from the most recent quarter represents a sustainable inflection in profitability or a one-time outperformance driven by non-recurring factors.
Wall Street Analyst Ratings for AZN
Wall Street consensus on AstraZeneca PLC remains divided, with recent analyst actions reflecting contrasting views on the stock's risk-reward profile. Berenberg Bank reiterated a Buy rating on July 13, 2026, while Jefferies also maintained its Buy recommendation through multiple reiterations on June 9 and June 26, per Wall Street analyst reports. In contrast, Deutsche Bank has taken a bearish stance, reiterating a Sell rating on both June 11 and June 26, 2026, creating a notable divergence among major research desks. The split between bullish and bearish coverage highlights ongoing debate around AstraZeneca's premium valuation, with the P/E ratio of 33.06 serving as a key friction point, according to SID consensus data. Two of the three covering firms maintain Buy ratings, establishing a two-thirds majority bullish skew among recent actions. The frequency of reiterations from both Jefferies and Deutsche within a single month suggests heightened analytical attention amid recent share price weakness.
